A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
Sponsor: Rabin Medical Center
Terminated
Slow accrural, dismal results
Listed as NCT03016091, this PHASE2 trial focuses on Anaplastic Meningioma and Atypical Meningioma and remains terminated or withdrawn. Sponsored by Rabin Medical Center, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Mar 2025 — Sep 2025 [monthly]
Terminated PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Sep 2024 — Feb 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
▶ Show 6 earlier versions
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
May 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — May 2019 [monthly]
Not Yet Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Rabin Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .